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Background: Despite hospitalization for exacerbation being a high-risk event for morbidity
and mortality, there is little consensus globally regarding the assessment and management of
hospitalised exacerbations of COPD. We aimed to establish a consensus list of symptoms,
physiological measures, clinical scores, patient questionnaires and investigations to be
obtained at time of hospitalised COPD exacerbation and follow-up.
Methods: A modified Delphi online survey with pre-defined consensus of importance,
feasibility and frequency of measures at hospitalisation and follow-up of a COPD exacerba
tion was undertaken.
Findings: A total of 25 COPD experts from 18 countries contributed to all 3 rounds of the
survey. Experts agreed that a detailed history and examination were needed. Experts also
agreed on which treatments are needed and how soon these should be delivered. Experts
recommended that a full blood count, renal function, C-reactive protein and cardiac blood
biomarkers (BNP and troponin) should be measured within 4 hours of admission and that the
modified Medical Research Council dyspnoea scale (mMRC) and COPD assessment test
(CAT) should be performed at time of exacerbation and follow-up. Experts encouraged
COPD clinicians to strongly consider discussing palliative care, if indicated, at time of
hospitalisation.
Interpretation: This Europe-wide consensus document is the first attempt to standardise
the assessment and care of patients hospitalised for COPD exacerbations. This should be
regarded as the starting point to build knowledge and evidence on patients hospitalised for
COPD exacerbations.
Keywords: COPD, disease exacerbation, hospitalisation, patient care, consensus
development, expert opinion

Introduction
Hospitalised exacerbations of chronic obstructive pulmonary disease (COPD)
account for a significant proportion of bed pressures and hospital costs throughout
the world, including Europe1,2 and North America.3 These exacerbations also
confer a high risk of in-hospital mortality of approximately 5–8%4,5 and carry up
to 58% risk of re-admissions within 1 month6,7 and up to a 20–25%5 risk of
mortality in the 12 months following discharge.
Major international COPD guidelines8,9 provide clinicians with very little gui
dance for standardisation of clinical assessment, examination, laboratory and radi
ological tests and treatment in hospitalised exacerbations of COPD (HECOPD).
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There is also no consensus on patient follow-up frequency
and the details on what should be measured during the post
hospitalisation follow-up phase. For example, the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
suggests measuring spirometry in everyone hospitalised
for an exacerbation of COPD.8 A 2016 European audit4
showed that more than half of patients admitted to hospital
for an exacerbation of COPD had never had a spirometry
recorded. Similarly, the GOLD report8 recommends the
measurement of an arterial blood gas, yet uptake of this
is incomplete.4 Even in long-term treatment decisions,
such as the use of long-term oral corticosteroids, physician
practices do not match the guidelines.10
Our colleagues in other fields of acute hospital care,
such as cardiology and rheumatology, have enviable evi
dence-based guidelines.11,12 These often define what,
when, how and the frequency a patient should have
assessment of symptoms, tests, outcomes and treatments.
This has led to standardisation of treatment protocols and
clinical trial endpoints. Without a doubt, this has played
a major contributory role in the improvements in patient
outcomes in rheumatoid arthritis13 and myocardial
disease.14 There are also clear lessons that COPD specia
lists can take on board from other clinical areas. In
2004,15 the Outcome Measures in Rheumatology
(OMERACT) collaborative set out to achieve an expert
consensus statement on different outcome measures and
treatment goals in caring for patients with psoriatic arthri
tis. Like for HECOPD, they set out from a place of
limited evidence and aimed to achieve a standardised
starting point to then build their evidence base on.
Within a few years, the collaborative achieved global
expert consensus on outcomes in psoriatic arthritis
care,16 which was then taken up by major international
professional bodies.17
With this context, we have investigated consensus as
well as the areas of disagreement in the evaluation of the
expert view on demographic, clinical characteristics,
comorbidities, investigations and clinical outcomes for
patients who are hospitalised for acute exacerbations of
COPD as part of the CICERO collaboration.18

Methods
This study used a modified, 3-round online survey based
on the Delphi method19 to establish a defined list of vari
ables that should be measured at the time of a HECOPD.
The survey was conducted via a secure online survey
platform (surveymonkey.com). The variables were divided
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into symptoms, examination findings, co-morbidities, clin
ical scores, laboratory tests, point of care test (eg, ECG,
spirometry), other tests (eg, radiology, detailed lung func
tion tests), treatments and clinical outcomes of importance.
All the items were assessed for use at time of hospitalisa
tion and at the post hospitalisation follow-up phase.
Excepting the history-taking sections, the feasibility of
undertaking each of these assessments and treatments
was also assessed. Ethics or institutional review board
approval was not required. This survey was exempt from
approval as it was non-invasive, undertaken voluntarily by
medical professionals and did not involve any patients.

Expert Selection
To understand current practice in Europe and to derive
a consensus list of variables, we set out to invite
a diverse panel of COPD experts from as many countries
in Europe as possible. Policy Delphi20 methodologists
recommend a panel size of between 15–40 experts to
achieve an appropriate balance between points of view.
Experts were contacted by the European Respiratory
Society if they met 2 or more of the following criteria:
1. Board-certified pulmonologists who currently spend
at least 20% of their time caring for patients hospi
talised for acute exacerbation of COPD
2. Evidence of publication of important COPD
research relevant to assessment or management of
patients hospitalised for exacerbations of COPD
3. A history of participation in the development of
local or national guidelines for the management of
COPD

Delphi Process
The modified Delphi process consisted of 3 iterative
rounds (subsequently called rounds 1, 2 and 3). Each
expert was provided a unique secure link to an online
questionnaire platform. The variables were listed in
groups, and experts were asked to rate the importance,
feasibility and a suggested frequency on a Likert scale.
Experts were reminded that the survey sought to obtain
their opinion on clinical care for HECOPD. Free text
capability for expert comments were sought for each sec
tion. Any new item suggested was added to the following
round of the electronic survey. Members then returned the
completed online surveys anonymously. Experts were
asked to return surveys within a 3-week period.
Reminder e-mails were sent to encourage completion,
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and extensions were given when necessary. This is sum
marised in Figure 1.
Consensus, dissensus and stability criteria for the
Delphi process were pre-determined prior to Delphi pro
cess commencement. Consensus21,22 was defined as an
interquartile range (IQR) of ≤1 for a 4- or 5-point Likert
scale item. For 3-point Likert scales and for Yes/No items,
an IQR of 0 was needed to achieve consensus. A Wilcoxon

Ramakrishnan et al

signed rank test was performed on paired results of
expert’s responses to assess stability of responses between
rounds. If the responses were not statistically significantly
different (p value ≥ 0.05), responses were considered
stable. At the completion, any item that reached a score
of “important“, “important to very important“ or “very
important“ was included in the final consensus list. The
corresponding feasibility and frequency were also reported

Figure 1 Schematic illustrating the Delphi survey process.
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if consensus was achieved. If items were rated “neutral“ or
“neutral to important“, they were assigned as “to be con
sidered” in any future evaluation. Items where consensus
was not achieved are also reported.

Variable Selection
A detailed literature review was undertaken by SR and MB
to assess the current evidence basis for symptoms, exam
ination findings, co-morbidities, clinical scores, laboratory
tests, point of care test (eg, electrocardiogram, spirometry),
other test (radiology, detailed lung function tests), treat
ments and clinical outcomes of importance for use in hos
pitalised patients with exacerbation of COPD (search
criteria used are available in supplementary Table 1), prior
to design of the Delphi survey. A final decision for survey
input was made at a face to face meeting by SR, MB, WJ
and AH.

Round 1
As we were aiming to establish experts’ views on many
variables and many aspects of the variable (importance,
frequency, feasibility etc), a skip logic was programmed to
help reduce the survey burden. If an expert marked a variable
as “Not at all important” on the importance Likert scale, the
item was removed from the survey for that expert for all
subsequent lower order items (eg, feasibility). In other words,
if experts rated something as not important, then aspects of
that item, eg, feasibility and frequency, were deemed irrele
vant for the remainder of round 1.

Round 2
All items that achieved consensus in round 1 were
removed from round 2. If consensus was only achieved
on one aspect of the item, for example the importance of
a particular clinical test, but not the feasibility or fre
quency, the importance section was not re-evaluated in
round 2, but the other aspects were re-evaluated. Any
variable that was re-evaluated was accompanied by
a histogram of the previous round’s expert responses and
a median of the responses. Any items suggested by experts
in round 1 were also included in round 2. No skip logic
was programmed for round 2.

Round 3
Again, variables achieving consensus were removed. For
items that did not achieve consensus, stability was
assessed. If a variable remained in dissensus and
remained stable, the item was removed and marked as
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“stable disagreement”. If a variable remained in dissen
sus but had changed significantly, the item was marked
for re-evaluation in round 3. Like round 2, any new
suggestions from experts in round 2 were included.
Questions were modified for clarity and/or specificity
in response to experts’ suggestions. There was no skip
logic. Any variable that was re-evaluated was accompa
nied by a histogram of the previous round’s expert
responses and a median of the responses for both
rounds.

Results
A total of 25 COPD experts from 19 European countries
completed all 3 rounds of the Delphi survey. There were
3 experts from the UK; 2 each from the Netherlands,
France, Germany and Italy; and 1 each from Belgium,
Spain, Switzerland, Portugal, Croatia, Estonia, Serbia,
Latvia, Sweden, Turkey, Slovenia, Finland, Greece and
Poland. There were 8 (32%) female experts, and the
majority were aged between 41–50 years (56%). All
experts worked in the field of COPD in secondary or
tertiary/academic institutions. On average, experts spent
22% of their time caring for respiratory inpatients. All
but one of the experts were actively involved with
research into COPD care. After round 2, no further
new items were recommended to gain consensus. The
survey was sent and completed prior to the coronavirus
disease 2019 (COVID-19) pandemic.

Expert Consensus Opinion During an
Acute Hospitalised Exacerbation of
COPD
Symptoms
There were 29 symptoms that were assessed for impor
tance, method of symptom data capture (binary vs severity
scale) and frequency of symptom capture. After 3 rounds,
no consensus was achieved on 3 items (low mood, sneez
ing and poor sleep). A further 2 symptoms, namely runny
eyes and itchiness, were excluded by experts. Of the
remaining 24 symptoms, experts recommend that 12
symptoms must be recorded at time of exacerbations and
12 that ought to be considered (see Table 1). The experts
endorse that most symptoms could be recorded in a binary
form (ie, present or absent). For the symptoms of cough
and sputum purulence respectively, experts could not agree
whether this should be reported quantitively (on a scale of
severity) or qualitatively (absent or present) after 3 rounds.

International Journal of Chronic Obstructive Pulmonary Disease 2021:16
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Table 1 Recommended Symptom Data Capture at Time of
Hospitalised Exacerbation
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Must Be Recorded

that treating physicians need only consider recording
some cardiac signs, such as heart murmurs, pulsus para
doxus, jugular venous pressure (JVP), in addition to body
weight at time of hospitalised exacerbations (see Table 2).
Experts agreed that menstrual cycle, forearm and quadri
ceps strength, abdominal distension, abdominal tenderness
and pulsatile liver edge did not need to be actively
recorded unless relevant to the patient history. The con
sensus list of clinical signs to elicit at the post hospitalisa
tion follow-up phase are listed in supplementary Table 2.

Symptoms

How to Measure

Frequency

Dyspnoea

Severity scale

Daily

Wheeze

Binary

Daily

Increased sputum volume

Binary

Daily

Sputum purulence

No consensus achieved

Daily

Cough

No consensus achieved

Daily

Fever

Binary

Twice a day to daily

Clinical Tests

Use of rescue medication

Severity scale

Daily

Increased inhaler use

Binary

Daily

Reduced exercise tolerance

Severity scale

Daily to once in admission

Confusion

Binary

Daily

Loss of consciousness

Binary

Daily

Orthopnoea

Binary

Daily to once in admission

Chest tightness

Binary

Daily

Chest pain

Binary

Daily

Haemoptysis

Binary

Daily

Cough at night

Binary

Daily

Myalgia

Binary

Daily

Fatigue

Binary

Daily

Drowsiness

Binary

Daily

Poor appetite

Binary

Daily

Palpitations

Binary

Daily

Sore throat

Binary

Daily

Runny nose

Binary

Daily

Headache

Binary

Daily

An expert consensus was reached on which tests should
be performed at the time of a severe hospitalised exacer
bation of COPD (see Table 3). Experts recommend that
a full blood count, renal function, C-reactive protein
(CRP), cardiac troponin and BNP are essential tests and
should be completed within 4 hours of hospitalisation.
Similar to this, the experts recommended that a chest
radiograph and ECG should be performed as soon as
possible. The optimum timing of when other essential
tests should be performed (namely arterial blood gas,
sputum cultures and viral swabs) could not be decided.
Other routinely available tests were recommended by
experts to be investigations to consider, reflecting on
occasion the healthcare system available to experts. This
included common tests such as lactate dehydrogenase
(LDH) and nasopharyngeal swab for non-influenza
respiratory viruses. Tests not included in the consensus
recommendation are listed in supplementary Table 3.
Experts could not agree on the importance of performing
any point of care assessment of lung function or inflam
mation at time of acute exacerbation (including peak flow,
spirometry and exhaled nitric oxide). All tests at the post
hospitalisation follow-up phase that were recommended
for consideration and excluded by expert consensus are
listed in supplementary Table 3.

Consider Recording

Co-Morbidities
Respondents recommended that a complete and detailed med
ical history was necessary at time of exacerbation. Some
medical history items, namely, history of atopy, osteoporosis,
chronic kidney disease, human immunodeficiency virus (HIV)
status and non-lung primary malignancy were rated as being
less important for routine recording but should be considered.

Clinical Signs
Consensus was achieved on the importance of recording
respiratory clinical signs. However, expert opinion was

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

Clinical Scores and Questionnaires
A wide range of related clinical severity scores and ques
tionnaires were assessed for their utility and feasibility (see
supplementary Table 4). Experts felt that only 3 should be
done at time of hospitalised exacerbation; these were the
modified Medical Research Council (mMRC) dyspnoea
scale, the COPD assessment test (CAT) and asking about
frequency of exacerbations (frequent exacerbator pheno
type) (see Table 4). The majority of clinical scores/question
naires were excluded by consensus (see supplementary
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Table 2 Recommended Clinical Signs Data Capture at Time of Hospitalised Exacerbation
Clinical Signs

Inclusion

Frequency

Blood oxygen saturation

Must

At least once every 4 to 12 hours

Supplemental oxygen amount

Must

At least once every 12 hours

Heart rate

Must

At least once every 12 hours

Respiratory rate

Must

At least once every 12 to 24 hours

Use of accessory respiratory muscles

Must

At least once every 12 to 24 hours

Change in mental state

Must

At least once every 12 to 24 hours

Blood pressure

Must

At least once every 12 to 24 hours

Temperature

Must

At least once every 12 to 24 hours

Wheeze on assessment/examination

Must

At least once every 12 to 24 hours

Irregular pulse

Must

At least once every 12 to 24 hours

Silent chest

Must

At least once every 12 to 24 hours

Orthopnoea

Must

At least once every 12 to 24 hours

Crackles

Must

At least once a day

Ronchi

Must

At least once a day

Pursed lip breathing

Must

At least once a day

Ankle oedema

Must

At least once a day

Presence of raised JVP

Must

At least once a day

Colour of sputum

Must

At least once a day

Body mass index

Must

Once during admission

Degree of raised JVP

Consider

Once a day to once during admission

Heart murmurs

Consider

Once a day to once during admission

Hoover’s sign

Consider

Once a day to once during admission

Weight

Consider

Once a day to once during admission

Pulsus paradoxus

Consider

Once a day to once during admission

Abbreviation: JVP, jugular venous pressure.

Table 5), including the SGRQ, APACHE and EXACT-Pro.
These recommendations also extended to the post hospitali
sation follow-up phase (see supplementary Table 5).

Pharmacological Treatments (When Indicated)
Expert opinions related to treatments, when clinically indi
cated, achieved the greatest amount of consensus early in the
Delphi, including the treatments that need to be given and
when they should be commenced (see Table 5). When clini
cally indicated, experts recommended that patients hospita
lised with an exacerbation of COPD be treated with systemic
corticosteroids and antibiotics, for 5 to 7 days in total, with
systemic corticosteroids dosing equivalent to 30–50 mg of
prednisolone daily. Experts recommended that nebulised
therapy duration should be given for a maximum of 5 days,
although there was a greater variation of opinion on duration.
Experts strongly recommended that long-term inhaler opti
misation should be performed prior to discharge.

Non-Pharmacological Treatments
Experts expected smoking cessation advice to be provided at
every hospitalisation, in addition to seeing a respiratory phy
siotherapist. A referral to pulmonary rehab was considered
a routine requirement. Although ideal, seeing a COPD specialist
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Outcomes at the Post Hospitalisation Follow-Up
Phase
The consensus opinion among experts was that patients
should only be considered stable at 6 weeks (median,
IQR 6 to 12 weeks) post hospitalisation for COPD
exacerbation. Experts were also able to make recommen
dations on the list of outcomes that should be used to
define “treatment failure”, both in clinical practice and in
research (see Table 6).

Potential Controversies
Experts recommended that an echocardiogram should be part
of clinical care for patients with a hospitalised exacerbation
of COPD following round 3; however, no consensus was
reached as to when this should be performed (ie, in hospital
or after discharge) or whether this should be performed
routinely or only if clinically indicated. Computed tomogra
phy (CT) scans of the thorax and peak flow measurements
led to strongly conflicting opinions of experts saying it was

International Journal of Chronic Obstructive Pulmonary Disease 2021:16
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Table 3 Recommended Tests to Perform at Time of Hospitalised Exacerbation of COPD
Tests

Inclusion

Within 4 Hours

Within 8 Hours

Full blood count

Must

✓

Urea, electrolytes, creatinine

Must

✓

Troponin

Must

✓

BNP

Must

✓

CRP

Must

✓

Glucose

Must

No consensus achieved on time to first test

Liver function tests

Must

No consensus achieved on time to first test

ABG

Must

No consensus achieved on time to first test

Chest X-ray

Must

As soon as possible during admission

Electrocardiogram

Must

As soon as possible during admission

Echocardiogram

Must

No consensus achieved on time to first test

Sputum MCS

Must

No consensus achieved on time to first test

Influenza viral throat swab

Must

No consensus achieved on time to first test

6-minute walk test

Must

No consensus achieved on time to first test

Lactate dehydrogenase

Consider

No consensus achieved on time to first test

High-sensitivity CRP

Consider

No consensus achieved on time to first test

Procalcitonin

Consider

No consensus achieved on time to first test

Urine dipstick

Consider

No consensus achieved on time to first test

Viral throat swab

Consider

No consensus achieved on time to first test

CT scan of thorax

Consider

No consensus achieved on time to first test

Grip strength

Consider

No consensus achieved on time to first test

Quadricep strength

Consider

No consensus achieved on time to first test

Overnight oximetry

Consider

No consensus achieved on time to first test

Within 12 Hours

Within 24 Hours

Within Admission

Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; ABG, arterial blood gas; MCS, microscopy, culture and sensitivities; DLCO, diffusing capacity of lung
for carbon monoxide; CT, computed tomography.

either “not at all important” or “very important”, and these
polarised opinions were not resolved after 3 rounds.

the management of patients with HECOPD. These included
symptoms, examination findings, co-morbidities, clinical
scores, laboratory tests, point of care tests and treatments.

Discussion

This is the first proposal of standardised data collection in
clinical practice for severe hospitalised exacerbations of
COPD (see https://www.cicero-copd.net/ for hospital

We report here the expert consensus recommendations from
a detailed Delphi study in standardisation of measurements in

Table 4 Recommended Clinical Scores and Questionnaires to Be Taken at Time of Hospitalised Exacerbation
Clinical Score/Questionnaires

Inclusion

Frequency

mMRC dyspnoea index

Must

At the start and end of admission

COPD assessment test

Must

At the start and end of admission

Frequent exacerbator phenotype

Must

Once during admission

BODEx

Consider

Once during admission

CURB-65

Consider

Once during admission

Glasgow Coma Scale

Consider

Once during admission

GOLD I–IV

Consider

Once during admission

GOLD A–D

Consider

Once during admission

Visual analogue scale for symptoms

Consider

At the start and end of admission

Early warning chart*

Consider

Daily

HADS*

Consider

Once during admission

DECAF*

Consider

Once during admission

Clinical COPD questionnaire*

Consider

No consensus achieved

Notes: *European experts felt that these scores may not be feasible in some centres. References for clinical scores and questionnaires listed in Supplementary Table 4.
Abbreviations: mMRC, modified Medical Research Council; BODEx, body mass index, degree of airflow obstruction, dyspnoea, exacerbations; CURB-65, confusion, urea,
respiratory rate, blood pressure, age >65; GOLD, global initiative for chronic obstructive lung disease; HADS, hospital anxiety and depression scale; DECAF, dyspnoea,
eosinopenia, consolidation, acidemia and atrial fibrillation.
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Table 5 Recommendations Regarding Treatment Allocation, if Indicated, at the Time of Hospitalised Exacerbation of COPD
Treatment

Within 30 Minutes

Oxygen
Nebulised short-acting beta agonists

✓
✓

Nebulised short-acting muscarinic agents

✓

Systemic corticosteroids
Intravenous fluids

✓
✓

Non-invasive ventilation

✓

Within 4 Hours

Antibiotics
Opiates

✓
✓

Diuretics
Chest physiotherapy

✓

Within 24 Hours

✓
✓

Assisted mobilisation

Table 6 Recommended Treatment Failure Assessments at 30 Days After Hospitalised Exacerbation of COPD
Treatment Failure Outcome to Assess

Inclusion

Mortality

Must

Intensive care admission requirement

Must

Re-admission
Re-treatment with steroids and/or antibiotics for COPD exacerbation

Must
Must

Health care utilisation (any of hospital presentation, primary care or urgent care visit)

Must

Length of stay
New or worsening co-morbidities following the index exacerbation event (eg, diabetes, osteoporosis)

Must
Must

Increase in short-acting inhaled therapy

Must

Cumulative use of systemic steroids
Change in symptom scores

Must
Consider

Quality of life scores

Consider

exacerbation standardisation tool). This Delphi survey is
a robust method to obtain consensus on standardisation of
many aspects of hospitalised COPD management and pro
vides a real-life perspective on the components prioritised by
COPD physicians. The experts selected represent COPD
physicians from across Europe with diverse health systems.
We believe our high retention rate of experts throughout the
three survey rounds is indicative of the importance of gaining
standardisation for hospitalised exacerbation management, in
addition to certain features of programming such as skip
logics which ultimately reduced participant “click” burden.
We found that, overall, there was a great deal of consensus
amongst COPD experts. We specifically assessed importance
and feasibility separately to establish an ideal set of mea
sures; this assessment of a clinician's opinion on importance
and how feasible a measure is has not been made before.8 We
also pre-defined consensus and stability criteria prior to study
commencement to prevent post hoc adjustments to affect
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inclusion threshold.22 We found very few occasions where
an item (eg, a question in the survey) was found to be rated
important and regarded as not feasible simultaneously.
As expected, all experts agreed that a detailed medical
history and physical exam were important at time of
hospitalisation, as per current recommendations.8
However, the inability of experts to agree on how to
measure two very common symptoms, such as cough
and sputum purulence, clearly exemplifies the need to
urgently standardise recording of these symptoms. Our
effort will almost certainly aid clinical practice, research
practice and consequently patient outcomes. Furthermore,
it is recognised that cardiovascular disease is a substantial
cause of morbidity and mortality in patients with
COPD;23 however, the expert opinion in our survey pre
dominantly graded respiratory physical signs of higher
importance than cardiac signs. This may reflect bias in
asking respiratory experts or that simply assessing cardiac
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signs alone is insufficient to address cardiovascular risk.
Moreover, it is worth noting that our experts recommend
that cardiac biomarkers such as BNP, troponin, ECG and
echocardiogram are essential tests in the management of
a patient hospitalised with an exacerbation, and in the
case of BNP, troponin and an ECG these should be
performed within 4 hours (or as early as possible) of
the admission. This recommendation highlights the
importance of assessing cardiovascular risk in patients
with COPD, where mortality is high.23 It is recognised
that there is an increased risk of cardiovascular events
within 30 days of hospitalisation for an exacerbation of
COPD24 and that it is highly likely that clinical or subclinical cardiovascular disease may worsen during
a severe exacerbation.
The experts’ views on blood, radiology and assess
ments of lung function at the time of hospitalised COPD
exacerbation were interesting. Unlike asthma guidelines,
current COPD guidelines do not recommend point of care
lung function testing during an exacerbation.8,9 This was
also reflected by our experts not agreeing on any point of
care test (including peak flow) and thus not recommending
this as an investigation at time of hospitalisation. This
could reflect the limitations with spirometry or peak flow
as an available tool25 and the lack of evidence to suggest it
alters clinical management at the time of an exacerbation.
This contrasts with the expert consensus regarding the
value of spirometry at time of follow-up, as a diagnostic
requirement. It is conceivable, however, that other more
sensitive tools assessing airway obstruction, such as
impulse oscillometry testing,26 need to be considered at
time of hospitalisation or follow-up.
In contrast to this, there was expert consensus and
recommendation that full blood count, renal function and
CRP should be performed within 4 hours of an admission.
The use of the peripheral blood eosinophil count27 and
serum C-reactive protein28 during a HECOPD is still being
evaluated. Meanwhile, although other tests were consid
ered to be important, there was no consensus as to when
these should be performed. We believe that the variability
in the severity of HECOPD could impact on timeline
decision-making and is thus reflected as dissensus in this
survey.
The experts recommended that a chest radiograph
should be performed as soon as possible within the admis
sion. This is in line with current recommendations. Chest
X-ray is used frequently29–31 despite evidence showing
that it rarely alters30 clinical management. Research on
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the value of a CT of the chest during HECOPD is
ongoing;32 whilst the relative infeasibility of CT scans
likely contributed to strongly polarised views on its impor
tance at time of HECOPD.
Finally, experts agreed that only the mMRC33 and the
CAT34 must be assessed at time of hospitalisation. Despite
there being a wide variety of risk tools to assess COPD
exacerbation and mortality risk, external validation of
these risk tools at the time of a hospital admission is
limited35 and is likely to have attributed to expert opinion
on which risk tools/scores are required at the time of
a hospitalisation of COPD.
Following this expert consensus, we have defined
a patient to be stable following a hospitalisation of
COPD at 6 weeks, with a range of timepoints from 6 to
12 weeks to define stability, after hospitalisation. We
believe it is of great importance that our experts were
able to provide opinion on how to define a treatment fail
ure. Our experts recommended that a treatment failure
outcome should be measured at 30 days; in addition to
currently approved definitions (of death or re-treatment for
example), we should also capture outcomes related to
cumulative systemic corticosteroid use, use of shortacting inhaler use and new or worsening of concomitant
co-morbidities. These additional components seek to
address harm of treatment, where the evidence is now
increasing.36
There are several limitations to discuss. Firstly, it is
important to note that the consensus decisions derived
from this survey reflect expert opinion, and there is little
evidence supporting the practice of measuring these out
comes at time of hospitalisation for an exacerbation of
COPD. However, due to the paucity of evidence or best
practice, this is where the Delphi method works best. In
particular, this Delphi approach in management of hospi
talised COPD exacerbations can serve to act as
a springboard to start standardising, building evidence
and importantly to improve care. We feel that COPD
physicians should not accept the status quo simply because
there is no evidence to guide change. Secondly, as
expected,19 an expert-led Delphi process would favour
more detail and intervention than that which is potentially
plausible in day to day practice. To resolve this, we spe
cifically asked about the feasibility of all items, especially
considering local costs, and practice limitations. All the
items proposed reached a rating of “feasible to very fea
sible“. We believe that our success at bringing together
a broad expert panel from across Europe makes this
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document workable in clinical practice across Europe.
This has led to recommendations of symptoms, signs,
tests and outcomes which are all eminently feasible.
A further limitation is that our experts were pre-selected
pulmonologists practising in Europe. This may potentially
make our results difficult to generalise to low- and middleincome countries; however, we feel this limitation will
only apply to the selection of investigations at the time
of a hospitalised exacerbation. The exclusion of allied
health professionals from the expert panel could also
limit the generalisability/acceptability of the proposed
standardisation consensus. As part of the CICERO clinical
research collaborative, we are now seeking patients' views
on our expert consensus through a multi-national, multilingual survey, run in collaboration with the European
Lung Foundation. This standardisation is also being
piloted in a Europe-wide cohort study of 1000 hospitalised
COPD exacerbations, another pre-defined goal of the
CICERO collaboration. These novel, patient and end-user
driven validation attempts are unique in clinical care stan
dardisation. Finally, we limited the survey to three rounds
a priori, where further rounds may yield further
consensus,19 although in current practice a minimum of 3
rounds are commonly recommended.22 The statistical
approaches used to define consensus and dissensus, and
the use of the Wilcoxon signed rank test could have falsely
shown stability. However, very few elements failed to
achieve stability of either consensus or dissensus after 3
rounds.
In conclusion, we have developed an expert consensus
tool through a pre-defined Delphi process, that recom
mends which measures should be undertaken as part of
standardisation of routine clinical care. To improve COPD
clinical care, the respiratory field should move beyond the
status quo from a position of limited standardisation.
Adoption of this expert consensus will provide the first
starting point to do this for patients hospitalised for
exacerbations of COPD.

Acknowledgments
We are very grateful to all the experts who contributed
generously to this project, including Alan Altraja;
Giovanna Elisiana Carpagnano; Joanna ChorostowskaWynimko; Christian Clarenbach; Aikaterini Dimakou;
Marta Drummond; Aleksandra Dudvarski Ilic; Matjaz
Flezar; Ana Hećimović; Hannu Kankaanranta; Huib
Kerstjens; Nurdan Köktürk; Jose Luis Lopez-Campos
Bodineau; Eric Van Ganse. We also thank Ms Alessandra

330

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

Marguerat and Dr Elise Heuvelin at the European
Respiratory Society for their technical and programming
support.
Sanjay Ramakrishnan was supported by the National
Institute for Health Research (NIHR) Oxford Biomedical
Research Centre (BRC). The views expressed are those of
the author and not necessarily those of the National Health
Service, the NIHR or the Department of Health.

Disclosure
Dr. Ramakrishnan reports non-financial support from
AstraZeneca, PhD scholarship from Australian Government
Research Training Program (RTP) and junior researcher
salary support from National Institute for Health Research
(NIHR) Oxford Biomedical Research Centre (BRC), during
the conduct of the study and outside the submitted work.
Dr. Janssens reports grants from Chiesi, AstraZeneca
and GSK, advisory board membership for Boerhinger
Ingelheim, AstraZeneca, Chiesi, GSK outside the sub
mitted work; and W. Janssens is cofounder of ARTIQ,
a spinoff company of KULEUVEN.
Dr. Burgel reports personal fees from AstraZeneca,
Boehringer Ingelheim, Chiesi, Novartis, Pfizer, Insmed
and Zambon, and grants and personal fees from GSK
and Vertex, outside the submitted work.
Dr. Contoli reports grants and personal fees from Chiesi,
AstraZeneca and GlaxoSmithKline, personal fees from
Boehringer Ingelheim, Alk-Abello, Novartis and Zambon
and grants from University of Ferrara, Italy, outside the sub
mitted work.
Dr. Franssen reports grants and personal fees from
AstraZeneca and Novartis, and personal fees from
Boehringer Ingelheim, Chiesi, GlaxoSmithKline and
TEVA, outside the submitted work.
Dr. Greening reports grants and personal fees from
GSK, personal fees and non-financial support from
Chiesi, and Boehringer Ingelheim outside the submitted
work.
Dr. Greulich reports personal fees from AstraZeneca,
Berlin-Chemie, Boehringer Ingelheim, Chiesi, GSK,
Novartis, grants from German Centre for Lung Research
(DZL), Marburg, Germany (Deutsches Zentrum für
Lungenforschung), grants and personal fees from Grifols and
CSL-Behring and lectures and advisory boards for GSK,
Novartis and Roche, outside the submitted work.
Dr. Gyselinck reports other non financial support from
KU-Leuven, outside the submitted work.

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 139.230.253.14 on 07-May-2021
For personal use only.

Dovepress

Dr. Quint reports grants from MRC, during the conduct of
the study; personal fees from GSK, grants from Asthma UK,
Chiesi, MRC and The Health Foundation, grants and personal
fees from AZ and BI, Bayer outside the submitted work.
Dr. Vanfleteren reports grants and personal fees from
AstraZeneca, personal fees from Novartis, GSK, Chiesi,
Menarini, Pulmonx, Resmed, Boehringer, Verona Pharma
and AGA Linde outside the submitted work.
Dr. Bafadhel reports grants and personal fees from
AstraZeneca, personal fees from Chiesi and GSK, grants
and non-financial support from AZ, non-financial support
from Chiesi and GSK and advisory board membership for
Albus Health and ProAxsis, outside the submitted work.
The authors report no other potential conflicts of interest
for this work.

References
1. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and
future costs of COPD in Iceland and Norway: results from the
BOLD study. Eur Respir J. 2009;34(4):850–857. doi:10.1183/
09031936.00166108
2. Ornek T, Tor M, Altın R, et al. Clinical factors affecting the direct
cost of patients hospitalized with acute exacerbation of chronic
obstructive pulmonary disease. Int J Med Sci. 2012;9(4):285–290.
doi:10.7150/ijms.4039
3. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact
of exacerbations on health care cost and resource utilization in
chronic obstructive pulmonary disease patients with chronic bronchi
tis from a predominantly medicare population. Int J Chron Obstruct
Pulmon Dis. 2012;7:757–764. doi:10.2147/COPD.S36997
4. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and
readmission of hospital-admitted COPD exacerbations: European COPD
audit. Eur Respir J. 2016;47(1):113. doi:10.1183/13993003.01391-2014
5. Groenewegen KH, Schols AM, Wouters EF. Mortality and
mortality-related factors after hospitalization for acute exacerbation
of COPD. Chest. 2003;124(2):459–467. doi:10.1378/chest.124.2.459
6. Jacobs DM, Noyes K, Zhao J, et al. Early hospital readmissions after
an acute exacerbation of chronic obstructive pulmonary disease in the
nationwide readmissions database. Ann Am Thorac Soc. 2018;15
(7):837–845. doi:10.1513/AnnalsATS.201712-913OC
7. Royal College of Physicians & British Thoracic Society. National COPD
Audit Programme: Outcomes from the Clinical Audit of COPD
Exacerbations Admitted to Acute Units in England 2014. London; 2017.
8. GOLD. Global Strategy for the Diagnosis, Management, and Prevention
of Chronic Obstructive Pulmonary Disease: 2020 Report. 2019.
9. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD
exacerbations: a European respiratory society/American thoracic
society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/
13993003.00791-2016
10. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in
chronic obstructive pulmonary disease. N Engl J Med. 2008;359
(15):1543–1554. doi:10.1056/NEJMoa0805800
11. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines
for the diagnosis and management of acute pulmonary embolism
developed in collaboration with the European respiratory society
(ERS): the task force for the diagnosis and management of acute
pulmonary embolism of the European society of cardiology (ESC).
Eur Heart J. 2019;41(4):543–603.

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

Ramakrishnan et al
12. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA
guideline for the management of st-elevation myocardial infarction:
a report of the American college of cardiology foundation/American
heart association task force on practice guidelines. J Am Coll Cardiol.
2013;61(4):e78–e140.
13. Sokka T. Long-term outcomes of rheumatoid arthritis. Curr Opin
Rheumatol.
2009;21(3):284–290.
doi:10.1097/BOR.0b013e328
32a2f02
14. Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and
long-term mortality after myocardial infarction in patients with and
without diabetes: changes from 1985 to 2008. Diabetes Care.
2012;35(10):2043–2047. doi:10.2337/dc11-2462
15. Gladman DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A.
OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis.
2005;64(suppl 2):ii115. doi:10.1136/ard.2004.032615
16. Ogdie A, de Wit M, Callis Duffin K, et al. Defining outcome mea
sures for psoriatic arthritis: a report from the GRAPPA-OMERACT
working group. J Rheumatol. 2017;44(5):697–700. doi:10.3899/
jrheum.170150
17. Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of
rheumatology/national psoriasis foundation guideline for the treat
ment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71
(1):2–29. doi:10.1002/acr.23789
18. Janssens W, Bafadhel M. The CICERO (collaboration in COPD
ExaceRbatiOns) clinical research collaboration. Eur Respir J.
2020;55(3):2000079. doi:10.1183/13993003.00079-2020
19. Linstone HA, Turoff M. The Delphi Method. MA: Addison-Wesley
Reading; 1975.
20. Turoff M. The policy delphi. In: Linstone HATM, editor. The Delphi
Method: Techniques and Applications. 2 ed. University of Michigan;
2002:80–96.
21. Rayens MK, Hahn EJ. Building consensus using the policy Delphi
method. Policy Polit Nurs Pract. 2000;1(4):308–315. doi:10.1177/
152715440000100409
22. von der Gracht HA. Consensus measurement in Delphi studies.
Technol Forecast Soc Change. 2012;79(8):1525–1536. doi:10.1016/
j.techfore.2012.04.013
23. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and
outcomes of diabetes, hypertension and cardiovascular disease in
COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/
09031936.00012408
24. Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of
chronic obstructive pulmonary disease and cardiac events. a post hoc
cohort analysis from the SUMMIT randomized clinical trial. Am
J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/
rccm.201711-2239OC
25. Rea H, Kenealy T, Adair J, Robinson E, Sheridan N. Spirometry for
patients in hospital and one month after admission with an acute
exacerbation of COPD. Int J Chron Obstruct Pulmon Dis.
2011;6:527–532. doi:10.2147/COPD.S24133
26. Jetmalani K, Timmins S, Brown NJ, et al. Expiratory flow limitation
relates to symptoms during COPD exacerbations requiring hospital
admission. Int J Chron Obstruct Pulmon Dis. 2015;10:939–945.
doi:10.2147/COPD.S78332
27. Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corti
costeroid therapy in patients admitted to hospital with COPD exacer
bation (CORTICO-COP): a multicentre, randomised, controlled,
open-label, non-inferiority trial. Lancet Respir Med. 2019;7
(8):699–709. doi:10.1016/S2213-2600(19)30176-6
28. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic
treatment in acute exacerbations of COPD admitted to hospital. Eur
Respir J. 2019.
29. Sha J, Worsnop CJ, Leaver BA, et al. Hospitalised exacerbations of
chronic obstructive pulmonary disease: adherence to guideline
recommendations in an Australian teaching hospital. Intern Med J.
2020;50(4):453–459. doi:10.1111/imj.14378

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

331

Dovepress

International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 139.230.253.14 on 07-May-2021
For personal use only.

Ramakrishnan et al
30. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs
in exacerbations of chronic obstructive pulmonary disease.
Diagnostic value. Arch Intern Med. 1989;149(11):2493–2496.
doi:10.1001/archinte.1989.00390110077016
31. Zimmermann SC, Tonga KO, Thamrin C. Dismantling airway dis
ease with the use of new pulmonary function indices. Eur Respir Rev.
2019;28(151):180122. doi:10.1183/16000617.0122-2018
32. Rangelov BA, Young AL, Jacob J, et al. Thoracic imaging at exacer
bation of chronic obstructive pulmonary disease: a systematic review.
Int J Chron Obstruct Pulmon Dis. 2020;15:1751–1787. doi:10.2147/
COPD.S250746
33. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA.
Usefulness of the medical research council (MRC) dyspnoea scale as
a measure of disability in patients with chronic obstructive pulmon
ary disease. Thorax. 1999;54(7):581. doi:10.1136/thx.54.7.581

34. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N.
Development and first validation of the COPD assessment test. Eur
Respir J. 2009;34(3):648. doi:10.1183/09031936.00102509
35. Bellou V, Belbasis L, Konstantinidis AK, Tzoulaki I, Evangelou E.
Prognostic models for outcome prediction in patients with chronic
obstructive pulmonary disease: systematic review and critical
appraisal. BMJ. 2019;367:l5358. doi:10.1136/bmj.l5358
36. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corti
costeroids and related harms among adults in the United States:
population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/
bmj.j1415

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal
The International Journal of COPD is an international, peer-reviewed
journal of therapeutics and pharmacology focusing on concise rapid
reporting of clinical studies and reviews in COPD. Special focus is
given to the pathophysiological processes underlying the disease, inter
vention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine
and CAS. The manuscript management system is completely online
and includes a very quick and fair peer-review system, which is
all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal

332

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

